secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)
CIK:        0001335105
Form:       8-K
Filed at:   2025-07-16T23:59:59+00:00
Accession:  0001641172-25-019900
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LIXTE Biotechnology regains Nasdaq equity compliance after $6.5M capital raise
------------------------------------------------------------------------------

- Received Nasdaq hearings panel notice of compliance with Listing Rule 5550(b)(1) requiring min $2.5M equity.
- Compliance achieved after closing $5.0M placement (July 2) and $1.5M direct offering (July 8).
- Subject to Panel Monitor through July 15, 2026; further deficiency triggers immediate hearing requirement.
- CEO states regaining compliance underscores financial health as clinical trials progress in ovarian, colon, sarcoma.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1335105/000164117225019900/0001641172-25-019900-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1335105/000164117225019900/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-019900

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer